8 completed, 1 recruiting, 1 terminated. 10 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 8, Recruiting 1, Terminated 1 |
| Phase 3 | 2 | Completed 2 |
Follow Ardelyx: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tenapanor in Synucleinopathy-Related Constipation Tenapanor, Placebo - Synucleinopathy, Parkinson's Disease | Phase 2 | Recruiting | Cedar Valley Digestive Health Center | 30 | 2025-01-01 | 2025-02-10 |
| 4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs Tenapanor, Placebo - Irritable Bowel Syndrome With Constipation (IBS-C) | Phase 2 | Completed | Ardelyx | 72 | 2024-07-24 | 2026-08-19 |
| A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia RDX013, Placebo - Hyperkalemia | Phase 2 | Completed | Ardelyx | 109 | 2021-01-11 | 2022-05-04 |
| Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy Tenapanor, Placebo, Phosphate Binder Agents - Hyperphosphatemia | Phase 2 / Phase 3 | Completed | Ardelyx | 236 | 2019-02-28 | 2023-03-06 |
| A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia RDX227675, Placebo - Hyperkalemia | Phase 2 | Terminated | Ardelyx | 60 | 2017-01-01 | 2019-12-26 |
| Dose Finding Study to Treat High Phosphate Levels in the Blood. AZD1722, Placebo - Hyperphosphatemia | Phase 2 | Completed | Ardelyx | 162 | 2014-03-01 | 2020-09-14 |
| The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C) AZD1722, Placebo - Constipation Predominant Irritable Bowel Syndrome | Phase 2 / Phase 3 | Completed | Ardelyx | 356 | 2013-08-01 | 2020-04-08 |
| A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria AZD1722, Placebo - Chronic Kidney Disease, Type 2 Diabetes Mellitus | Phase 2 | Completed | Ardelyx | 154 | 2013-05-01 | 2020-05-27 |
| Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis AZD1722 (in-patient), Placebo (in-patient), AZD1722 (out-patient) - End Stage Renal Disease, Chronic Kidney Disease Stage 5 | Phase 2 | Completed | Ardelyx | 88 | 2013-01-01 | 2020-08-10 |
| A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C) RDX5791 - Constipation Predominant Irritable Bowel Syndrome | Phase 2 | Completed | Ardelyx | 186 | 2011-05-01 | 2019-10-15 |
Hyperkalemia (2) · Hyperphosphatemia (2) · Kidney Failure, Chronic (2) · Renal Insufficiency, Chronic (2) · Albuminuria (1) · Constipation (1) · Diabetes Mellitus, Type 2 (1) · Parkinson Disease (1) · Synucleinopathies (1)
tenapanor (8) · Calcium Carbonate (1) · Sevelamer (1) · calcium acetate (1) · ferric citrate (1) · sucroferric oxyhydroxide (1)
United States (10) · Poland (1) · Slovakia (1) · United Kingdom (1)
David P Rosenbaum, Ph.D. (3) · David P Rosenbaum, PhD (2) · Geoffrey A Block, MD (1) · Harichandana Punukula, PharmD, MS (1) · Jocelyn Tabora (1) · Ravindra Mallavarapu, MD (1) · Richard A. Manfready, MD, AM, FACP (1)